- Home
- UGRO vs CYCN Comparison
UGRO vs CYCN Comparison
Compare UGRO & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- CYCN
- Stock Information
- Founded
- UGRO 2014
- CYCN 2018
- Country
- UGRO United States
- CYCN United States
- Employees
- UGRO N/A
- CYCN N/A
- Industry
- UGRO Industrial Specialties
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- UGRO Consumer Discretionary
- CYCN Health Care
- Exchange
- UGRO Nasdaq
- CYCN Nasdaq
- Market Cap
- UGRO 5.5M
- CYCN 6.5M
- IPO Year
- UGRO N/A
- CYCN N/A
- Fundamental
- Price
- UGRO $0.30
- CYCN $2.81
- Analyst Decision
- UGRO Strong Buy
- CYCN
- Analyst Count
- UGRO 1
- CYCN 0
- Target Price
- UGRO $3.00
- CYCN N/A
- AVG Volume (30 Days)
- UGRO 459.5K
- CYCN 21.8K
- Earning Date
- UGRO 07-07-2025
- CYCN 08-06-2025
- Dividend Yield
- UGRO N/A
- CYCN N/A
- EPS Growth
- UGRO N/A
- CYCN N/A
- EPS
- UGRO N/A
- CYCN N/A
- Revenue
- UGRO $59,985,138.00
- CYCN $2,081,000.00
- Revenue This Year
- UGRO N/A
- CYCN N/A
- Revenue Next Year
- UGRO $31.25
- CYCN N/A
- P/E Ratio
- UGRO N/A
- CYCN N/A
- Revenue Growth
- UGRO N/A
- CYCN N/A
- 52 Week Low
- UGRO $0.26
- CYCN $1.27
- 52 Week High
- UGRO $1.92
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- UGRO 36.47
- CYCN 41.24
- Support Level
- UGRO $0.29
- CYCN $3.02
- Resistance Level
- UGRO $0.33
- CYCN $3.16
- Average True Range (ATR)
- UGRO 0.04
- CYCN 0.21
- MACD
- UGRO -0.00
- CYCN -0.03
- Stochastic Oscillator
- UGRO 21.29
- CYCN 16.26
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.